Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: a modelling study
Medical Research Council · Imperial College London · +1 more institution
Abstract
COVID-19 has the potential to cause substantial disruptions to health services, due to cases overburdening the health system or response measures limiting usual programmatic activities. We aimed to quantify the extent to which disruptions to services for HIV, tuberculosis, and malaria in low-income and middle-income countries with high burdens of these diseases could lead to additional loss of life over the next 5 years.
Assuming a basic reproduction number of 3·0, we constructed four scenarios for possible responses to the COVID-19 pandemic: no action, mitigation for 6 months, suppression for 2 months, or suppression for 1 year. We used established transmission models of HIV, tuberculosis, and malaria to estimate the additional impact on health that could be caused in selected settings, either due to COVID-19 interventions limiting activities, or due to the high demand on the health system due to the COVID-19 pandemic.
Citation impact
- FWCI
- 26.97
- Percentile
- 100%
- References
- 17
Authors
54- ABAlexandra B. HoganCorresponding
Medical Research Council, Imperial College London
- BLBritta L. Jewell
Medical Research Council, Imperial College London
- ESEllie Sherrard-Smith
Medical Research Council, Imperial College London
- JFJuan F Vesga
Imperial College London, Medical Research Council
- OJOliver J. Watson
Medical Research Council, Imperial College London
Topics & keywords
- Pandemic
- Malaria
- Coronavirus disease 2019 (COVID-19)
- Tuberculosis
- Human immunodeficiency virus (HIV)
- 2019-20 coronavirus outbreak
- Virology
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Funding
- USUnited States Agency for International Development
- BABill and Melinda Gates Foundation
- WTWellcome Trust
- DFDepartment for International Development, UK Government
- ICImperial College London
- ECEuropean Commission
- DFDepartment for International Development
- MRMedical Research CouncilAwards: MR/R015600/1, MC_PC_19012
- EAEuropean and Developing Countries Clinical Trials PartnershipAward: EDCTP2